IDNA vs. XGEN.DE

Last updated Apr 2, 2026

Compare and contrast key facts about iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C (XGEN.DE).

IDNA and XGEN.DE are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. IDNA is a passively managed fund by iShares that tracks the performance of the NYSE FactSet Global Genomics and Immuno Biopharma Index. It was launched on Jun 11, 2019. XGEN.DE is a passively managed fund by Xtrackers that tracks the performance of the MSCI ACWI IMI Genomic Innovation Select ESG Screened 100. It was launched on Jul 12, 2022. Both IDNA and XGEN.DE are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.

Performance

IDNA vs. XGEN.DE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C (XGEN.DE). The values are adjusted to include any dividend payments, if applicable.

IDNA vs. XGEN.DE - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund	11.45%	17.26%	-0.72%	-7.63%	-22.55%
XGEN.DE Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C	-5.38%	21.23%	-2.93%	-2.86%	-5.79%

Different Trading Currencies

IDNA is traded in USD, while XGEN.DE is traded in EUR. To make them comparable, the XGEN.DE values have been converted to USD using the latest available exchange rates.

Returns By Period

In the year-to-date period, IDNA achieves a 11.45% return, which is significantly higher than XGEN.DE's -5.38% return.

IDNA

• 1D: 0.48%
• 1M: -5.56%
• YTD: 11.45%
• 6M: 20.68%
• 1Y: 48.06%
• 3Y*: 9.03%
• 5Y*: -7.93%
• 10Y*: —

XGEN.DE

• 1D: 2.65%
• 1M: -2.71%
• YTD: -5.38%
• 6M: 3.93%
• 1Y: 20.18%
• 3Y*: 2.96%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

IDNA vs. XGEN.DE - Expense Ratio Comparison

IDNA has a 0.47% expense ratio, which is higher than XGEN.DE's 0.30% expense ratio.

IDNA

iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund

XGEN.DE

Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C

Return for Risk

IDNA vs. XGEN.DE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IDNA

IDNA Risk / Return Rank: 85
IDNA Sharpe Ratio Rank: 85
IDNA Sortino Ratio Rank: 86
IDNA Omega Ratio Rank: 74
IDNA Calmar Ratio Rank: 93
IDNA Martin Ratio Rank: 88

XGEN.DE

XGEN.DE Risk / Return Rank: 30
XGEN.DE Sharpe Ratio Rank: 28
XGEN.DE Sortino Ratio Rank: 28
XGEN.DE Omega Ratio Rank: 26
XGEN.DE Calmar Ratio Rank: 34
XGEN.DE Martin Ratio Rank: 30

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IDNA vs. XGEN.DE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C (XGEN.DE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	IDNA	XGEN.DE	Difference
Sharpe ratio Return per unit of total volatility	1.75	0.94	+0.81
Sortino ratio Return per unit of downside risk	2.40	1.35	+1.05
Omega ratio Gain probability vs. loss probability	1.29	1.18	+0.11
Calmar ratio Return relative to maximum drawdown	3.66	1.37	+2.29
Martin ratio Return relative to average drawdown	11.65	4.45	+7.20
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

IDNA vs. XGEN.DE - Sharpe Ratio Comparison

The current IDNA Sharpe Ratio is 1.75, which is higher than the XGEN.DE Sharpe Ratio of 0.94. The chart below compares the historical Sharpe Ratios of IDNA and XGEN.DE, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	IDNA	XGEN.DE	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.75	0.94	+0.81
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.28	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.11	0.03	+0.08

Correlation

The correlation between IDNA and XGEN.DE is 0.62, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

IDNA vs. XGEN.DE - Dividend Comparison

IDNA's dividend yield for the trailing twelve months is around 1.06%, while XGEN.DE has not paid dividends to shareholders.

	TTM	2025	2024	2023	2022	2021	2020	2019
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund	1.06%	1.18%	0.98%	1.04%	0.54%	0.70%	0.26%	0.80%
XGEN.DE Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Drawdowns

IDNA vs. XGEN.DE - Drawdown Comparison

The maximum IDNA drawdown since its inception was -68.26%, which is greater than XGEN.DE's maximum drawdown of -33.22%. Use the drawdown chart below to compare losses from any high point for IDNA and XGEN.DE.

Drawdown Indicators

	IDNA	XGEN.DE	Difference
Max Drawdown Largest peak-to-trough decline	-68.26%	-37.58%	-30.68%
Max Drawdown (1Y) Largest decline over 1 year	-12.11%	-14.88%	+2.77%
Max Drawdown (5Y) Largest decline over 5 years	-68.26%	—	—
Current Drawdown Current decline from peak	-45.05%	-17.22%	-27.83%
Average Drawdown Average peak-to-trough decline	-36.05%	-19.46%	-16.59%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.81%	4.61%	-0.80%

Volatility

IDNA vs. XGEN.DE - Volatility Comparison

iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) has a higher volatility of 9.54% compared to Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C (XGEN.DE) at 7.04%. This indicates that IDNA's price experiences larger fluctuations and is considered to be riskier than XGEN.DE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	IDNA	XGEN.DE	Difference
Volatility (1M) Calculated over the trailing 1-month period	9.54%	7.04%	+2.50%
Volatility (6M) Calculated over the trailing 6-month period	18.22%	13.75%	+4.47%
Volatility (1Y) Calculated over the trailing 1-year period	27.75%	21.45%	+6.30%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	28.53%	19.83%	+8.70%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	29.68%	19.83%	+9.85%